Skip to main content

Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients

  • The Letter to this article has been published in Critical Care 2020 24:532

Trial registration

ChiCTR, ChiCTR2000029758. Registered 12 February 2020 - Retrospectively registered

Dear editors:

The COVID-19 pandemic has spread rapidly around the world and overwhelmed the supply of intensive care beds and ventilators; judicious ICU resource allocation is still one of the major challenges for clinicians and management [1]. The higher incidence of ARDS is the main reason for the burden of ventilator equipment. Early prediction of the occurrence and aggravation of ARDS in the ICU helps clinicians prepare for respiratory support equipment given the absence of effective treatment strategies. Moreover, early selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with V-V ECMO [2], which is a relatively scarce critical care resource. Therefore, early prediction of moderate-severe ARDS can help clinicians better allocate scarce ICU resources for COVID-19 crisis.

Neutrophil-to-lymphocyte ratio (NLR) is a simple biomarker of inflammation that can be measured during routine hematology. Previous studies have exhibited that higher NLR was associated with clinical deterioration and mortality for COVID-19 patients [3]. However, it remains unclear to what extent the significance of NLR would predict the occurrence of ARDS and ICU ventilator requirements for the COVID-19 crisis.

Patients diagnosed with severe COVID-19 from 21 hospitals in Sichuan Province between January 16 and March 15 were included in the analysis (ChiCTR2000029758). The maximum value of NLR, PLR, PCT, and CRP during the first 3 days after being diagnosed as severe COVID-19 was included in the analysis. Severe COVID-19 and ARDS were defined according to previous study [4] and Berlin definition [5], respectively. Multivariate logistic regression analysis and the area under the receiver operating characteristic (ROC) curve were used to analyze the ability of NLR in predicting ARDS.

Of totally 81 patients defined as severe COVID-19, 44 were diagnosed as ARDS. The baseline characteristics of the non-ARDS group and ARDS group are listed in Table 1. The area under the ROC curve for ARDS was 0.71, 0.591, 0.494, and 0.625 for NLR, PLR, PCT, and CRP, respectively. We used the median as the cutoff value to divide the patients into two groups. The high NLR group (NLR > 9.8) showed a higher incidence of ARDS (P = 0.005) and higher rate of noninvasive (P = 0.002) and invasive (P = 0.048) mechanical ventilation. Further, we defined moderate-severe ARDS as ARDS patients with oxygenation index less than 150. The area under the ROC curve for moderate-severe ARDS was 0.749, 0.660, 0.531, and 0.635 for NLR, PLR, PCT, and CRP, respectively (Fig. 1); the cutoff value of NLR for moderate-severe ARDS is 11.

Fig. 1
figure1

Moderate-severe ARDS prediction biomarkers in severe COVID-19 patients: NLR (0.749, 95% CI 0.624–0.850), PLR (0.660, 95% CI 0.530–0.775), PCT (0.531, 95% CI 0.401–0.658), and CRP (0.635, 95% CI 0.504–0.752)

Table 1 Baseline characteristics and clinical outcomes stratified by median NLR value

Our data revealed that NLR could be a valuable biomarker to recognize severe COVID-19 patients with moderate-severe ARDS, which facilitated clinicians to give effective respiratory supporting strategies and quickly find out moderate-severe ARDS patients who are at high indication for V-V ECMO.

Because of the mismatch of the oxygenation and lung function [6], a comprehensive consideration of immune indicators would improve early prediction for COVID-19 patients with “atypical” ARDS [6]. NLR is an extremely common laboratory test wherein the initial NLR value can be used to identify high-risk patients with moderate-severe ARDS, with the optimal threshold value of 11. This biomarker may be helpful in assessing the allocation of respiratory equipment in ICU patients and early assessment of ECMO. However, further clinical studies are needed to evaluate the benefits of NLR in ARDS.

Availability of data and materials

The datasets used for the analysis in the current study are available from the corresponding author on reasonable request.

Abbreviations

COVID-19:

Coronavirus disease 2019

ARDS:

Acute respiratory distress syndrome

ICU:

Intensive care unit

WHO:

World Health Organization

ECMO:

Extracorporeal membrane oxygenation

V-V ECMO:

Veno-venous extracorporeal membrane oxygenation

NLR:

Neutrophil-to-lymphocyte ratio

PLR:

Platelet-to-lymphocyte ratio

PCT:

Procalcitonin

CRP:

C-reactive protein

ROC:

Receiver operating characteristic

References

  1. 1.

    Liew MF, Siow WT, MacLaren G, See KC. Preparing for COVID-19: early experience from an intensive care unit in Singapore. Crit care (London). 2020;24(1):83.

    Article  Google Scholar 

  2. 2.

    Ramanathan K, Antognini D, Combes A, Paden M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8(5):518–26.

    CAS  Article  Google Scholar 

  3. 3.

    Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;S0163-4453(20)30208-5. https://doi.org/10.1016/j.jinf.2020.04.002.

  4. 4.

    Liao X, Chen H, Wang B, Li Z, et al. Critical care for patients with severe COVID-2019 in Sichuan Province, China——a provincial cohort study.medRxiv 2020.03.22.20041277; https://doi.org/10.1101/2020.03.22.20041277.

  5. 5.

    Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. Jama. 2012;307(23):2526–33.

    Google Scholar 

  6. 6.

    Gattinoni L, Coppola S, Cressoni M, et al. COVID-19 Does Not Lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201(10):1299–300. https://doi.org/10.1164/rccm.202003-0817LE.

Download references

Acknowledgements

We would like to thank all the medical workers involved in the rescue and the staff for collection of the data in Sichuan. We would like to thank all the investigators of the study of 2019 novel coronavirus pneumonia-infected critically ill patients in Sichuan province (SUNRISE).

Funding

This project was supported by Project of Novel Coronavirus Pneumonia in West China Hospital (HX2019nCoV027).

Author information

Affiliations

Authors

Contributions

AJM, JLC, MLD, and JY designed the study. MLD and YK participated in the rescue work on the clinical frontline. XLL and YK organized and managed the data and its quality. JLC and AJM collected the data, performed the statistical analysis, and drafted the manuscript with JY. All authors participated in the data interpretation. All authors read the manuscript carefully and approved the final version.

Corresponding author

Correspondence to Yan Kang.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the West China Hospital of Sichuan University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ma, A., Cheng, J., Yang, J. et al. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit Care 24, 288 (2020). https://doi.org/10.1186/s13054-020-03007-0

Download citation